Antiangiogenic gene therapy of cancer: Recent developments

Anita Tandle, Dan G. Blazer, Steven K. Libutti

Research output: Contribution to journalReview articlepeer-review

92 Scopus citations

Abstract

With the role of angiogenesis in tumor growth and progression firmly established, considerable effort has been directed to antiangiogenic therapy as a new modality to treat human cancers. Antiangiogenic agents have recently received much widespread attention but strategies for their optimal use are still being developed. Gene therapy represents an attractive alternative to recombinant protein administration for several reasons. This review evaluates the potential advantages of gene transfer for antiangiogenic cancer therapy and describes preclinical gene transfer work with endogenous angiogenesis inhibitors demonstrating the feasibility of effectively suppressing and even eradicating tumors in animal models. Additionally, we describe the advantages and disadvantages of currently available gene transfer vectors and update novel developments in this field. In conclusion, gene therapy holds great promise in advancing antiangiogenesis as an effective cancer therapy and will undoubtedly be evaluated in human clinical trials in the near future.

Original languageEnglish (US)
Article number22
JournalJournal of Translational Medicine
Volume2
DOIs
StatePublished - Jun 25 2004

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Antiangiogenic gene therapy of cancer: Recent developments'. Together they form a unique fingerprint.

Cite this